Biotech
Locus Biosciences
Locus Biosciences raises $152M Series C at $600M valuation
$152M
Total Raised
Series C
Latest Round
2015
Founded
150+
Employees
9201 University City Boulevard, Charlotte, NC 28223
1 min read
Quick Facts
Valuation
$600M
Latest Round Size
$152M
Latest Round Date
February 2024
Locus Biosciences: Series C Funding Round
Locus Biosciences has successfully raised $152M in Series C funding, reaching a valuation of $600M.
Company Overview
CRISPR-edited bacteriophages
Funding Details
The Series C round was led by Johnson & Johnson, with participation from Longitude Capital, Braeburn Capital, Domain Associates.
Company Information
- Headquarters: 9201 University City Boulevard, Charlotte, NC 28223
- Founded: 2015
- Employees: 150+
- Category: Biotech
Investment
Locus Biosciences plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Johnson & Johnson: Verified investor in Series C
- Longitude Capital: Verified investor in Series C
- Braeburn Capital: Verified investor in Series C
- Domain Associates: Verified investor in Series C
Key Investors
Johnson & Johnson
Lead Investor
Verified investor in Series C
Longitude Capital
Investor
Verified investor in Series C
Braeburn Capital
Investor
Verified investor in Series C
Domain Associates
Investor
Verified investor in Series C
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min read•$250M